Low Vitamin D and the gut problems: barrier, immunity, and microbiome - review

Vitamin D and Intestinal Diseases: Impact on Intestinal Immunity and Gut Barrier Function

Diseases (MDPI), 13 August 2026, https://doi.org/10.3390/diseases14080293

Erik Shorabaev, Amankeldi Sadanov, Baiken Baimakhanova, Saltanat Orasymbet, Irina Ratnikova, Bakhytzhan Kerimzhanova, Zhanar Assilova, Zaure Datkhayeva, Aknur Turgumbayeva

image

image

Summary by Claude - August, 2026

A narrative review (literature through May 2026, studies from 2004–2026) pulling together what vitamin D does in the gut and what the trials actually found.

Mechanism side: VDR signaling controls tight-junction proteins (ZO-1, claudins, occludin), keeps goblet and Paneth cells working, drives cathelicidin (LL-37) and β-defensins, pushes macrophages toward M2 and T cells toward Treg while suppressing Th1/Th17. Low D means impaired VDR signaling, a leakier barrier, dysbiosis, and more inflammation. VDR-knockout animals show more Bacteroidetes and Proteobacteria and fewer Firmicutes. The traffic runs both ways — gut bacteria also alter vitamin D metabolism, and lithocholic acid (a microbial bile-acid product) is itself a VDR agonist.

Clinical side, condition by condition:

Crohn's — RR 0.47 (95% CI 0.27–0.82) for relapse in patients already in remission — but that headline figure comes from only 2 trials. Across all 12 RCTs (458 IBD patients) the pooled relapse risk was 0.64 (0.46–0.89).

  • Ulcerative Colitis — 12 RCTs, 500–60,000 IU/day: individual studies encouraging. That's not a null result from twelve trials — it's near-absence of data.
  • IBS — 8 studies, 685 patients, 2,000–50,000 IU/day for 6–24 weeks: symptom severity (IBS-SSS) dropped significantly; quality of life did not.
  • Celiac — 27 studies, 1,137 patients vs 2,613 controls: 25(OH)D lower by 8.4 nmol/L (3.3 ng/mL), which normalized on a gluten-free diet. No VDR-polymorphism association.
  • Childhood infectious diarrhea — 4 studies, only 1 RCT: no benefit.
  • Colorectal cancer — supplementation associated with better overall survival; disease-free survival unclear.

What this does not show / limitations:

  • No new data — this is a summary of other people's work, and a narrative one, without systematic search protocol or risk-of-bias scoring.
  • Not one condition in Table 3 reports an achieved 25(OH)D level, so the 240-fold dose spread (250 to 60,000 IU) can't be tied to any blood level, which is likely why results look inconsistent.
  • Deficiency is defined at the low bar of 20 ng/mL.
  • Causation is unsettled throughout — low D in bowel disease may be malabsorption and inflammation rather than the cause; the authors say as much, calling for supplementation to "await confirmation from adequately powered randomized clinical trials."
  • Much of the mechanism section rests on animal and in-vitro work. ( The paper's reference numbering is broken: Table 3 cites [139] for Crohn's/UC, [140] for IBS, [141] diarrhea, [142] celiac, [143] CRC. The reference list has 138 = Valvano (IBD), 139 = Chong (IBS), 140 = Uwaezuoke (diarrhea), 141 = Lu (celiac), 142 = Vaughan-Shaw (CRC), 143 = Pludowski (guidelines). Everything in Table 3 is shifted by one. Anyone who follows those numbers lands on the wrong paper. The drift appears to start somewhere in the 130s and continue to the end.
  • The review discusses absorption barriers in Crohn's and celiac, then never once asks whether oral D3 in oil is the right delivery for a damaged gut. No calcifediol, no sublingual, no topical, no nanoemulsion — despite the UC study it cites having used nano vitamin D. - See Related in VitaminDWiki below
  • The authors disclose using generative AI for language editing, and the funding is a phase III GI trial grant held by a microbiology institute with an interest in probiotic co-therapy.

PDF

Related in VitaminDWiki

Gut, Gut-Friendly Vitamin D

Crohn's

Colitis

Microbiome

Stressors: UPF, Microplastics, etc.